RxDoctor Payments Data

Chad Gerrish, DO

Internal Medicine · Lansing, MINPI 1063738458

Payments from drug & device makers

$892in general payments, 2019–2025

Across 54 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$284
  • Lilly USA, LLC$115
  • GSK$105
  • Pfizer$78
  • AbbVie$67
  • Novo Nordisk$55
  • plus $189 from 8 others

What the payments were for

  • Food & beverage$86997%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$892 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$29,394
Medicare patients
128
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$77,134
XareltoRivaroxaban69$72,158
JardianceEmpagliflozin51$67,571
MounjaroTirzepatide54$67,506
JanuviaSitagliptin Phosphate42$53,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$42,929
TrulicityDulaglutide15$25,862
OzempicSemaglutide18$22,561
FarxigaDapagliflozin Propanediol14$19,524
RexultiBrexpiprazole13$18,769
MyrbetriqMirabegron16$16,952
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$12,578
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$12,362
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$11,339
TrintellixVortioxetine Hydrobromide12$10,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$115$93,36869 claims
PfizerEliquis$78$77,13473 claims
Johnson & JohnsonXarelto$52$72,15869 claims
Boehringer IngelheimJardiance$18$67,57151 claims
MerckJanuvia$14$53,45442 claims
GSKTrelegy Ellipta$105$42,92936 claims
Novo NordiskOzempic, Novolog$55$24,69731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →